Clinical Trial Update: Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating alemtuzumab on MRI surrogate markers of disease activity and repair in relapsing remitting multiple sclerosis; study completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Alemtuzumab (Alemtuzumab)

Snippet

Sponsor: University of Chicago | Conditions: Multiple Sclerosis | Phase 4 | Status: COMPLETED | Results posted: 2018-12-07